Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Dulaglutide

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Company n/r · Phase 3 · Completed · Enrollment 159

NCT07820111

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
obese , non diabetic ,recieve dulaglutiden/rn/rn/rn/r
obese , non diabetic ,receive SEMAGLUTIDEn/rn/rn/rn/r
obese , non diabetic ,receive TIRAZEPETIDEn/rn/rn/rn/r
obese , diabetic ,recieve dulaglutiden/rn/rn/rn/r
obese , diabetic ,receive SEMAGLUTIDEn/rn/rn/rn/r
obese , diabetic ,receive TIRAZEPETIDEn/rn/rn/rn/r

Not shown

  • obese , non diabetic ,recieve dulaglutide: endpoint not reported
  • obese , non diabetic ,receive SEMAGLUTIDE: endpoint not reported
  • obese , non diabetic ,receive TIRAZEPETIDE: endpoint not reported
  • obese , diabetic ,recieve dulaglutide: endpoint not reported
  • obese , diabetic ,receive SEMAGLUTIDE: endpoint not reported
  • obese , diabetic ,receive TIRAZEPETIDE: endpoint not reported